Advanced Filters
noise
Found 65,199 clinical trials
L Larry Allen, MD, MHS

Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure

An increasing number of guideline-directed medical therapies (GDMT) have been developed for patients with chronic heart failure with reduced ejection fraction (HFrEF). When used in combination at recommended doses, patients often experience significant improvements in cardiac function, quality of life, and survival.1,2 However, GDMT underuse occurs for the vast majority …

18 years of age All Phase N/A
s sherihan R. ahmed, MD

Combining Aspirin With Ticagrelor or Clopidogrel in Large-vessel Minor Stroke or TIA

Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.

18 - 75 years of age All Phase 3
X Xu Ruihua, MD

A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors

This is an open label, multi-center, multiple dose Phase IB/II study to evaluate the safety, tolerability and efficacy of SHR-1826 for injection in subjects with advanced solid tumors.

18 - 75 years of age All Phase 1/2

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

The goal of the study is to learn about the safety of Sacituzumab Tirumotecan and if people can tolerate it when given in the bladder and find the highest dose that people can take without having certain problems. Researchers will then choose a dose level of Sacituzumab Tirumotecan to use …

18 years of age All Phase 1/2
C Cathy Roy

Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

The investigators aim to compare the risk of mortality of Non-implantable carioverter defibrillator (ICD) vs. ICD management in patients with heart failure with reduced ejection fraction (HFrEF).

18 years of age All Phase N/A
X Xiao-Fan Zhu, M.D.

Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

Building upon the results from the CCCG-ALL-2015, CCCG-ALL-2020 multicenter study cohort, concurrent research findings, and the latest clinical trials, the CCCG-ALL-2025 I/HR-B-ALL is thus developed to further improve the event-free survival (EFS), and overall survival (OS), and quality of life (QoL) of children with intermediate- and highrisk B-cell childhood acute …

1 - 18 years of age All Phase 2/3
M Martin Breitwieser

Assessing AI-Supported Fracture Detection in Emergency Care Units

Brief Summary The purpose of this study is to determine if artificial intelligence (AI) can assist doctors in detecting broken bones more quickly and accurately in an emergency room setting. The study will also evaluate whether AI can save time and reduce costs in healthcare. The main questions to be …

years of age All Phase N/A
s sherihan R. ahmed, MD

Combining Aspirin With Ticagrelor or Clopidogrel in Minor Stroke or TIA

Along with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever minor stroke or TIA compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.

18 - 75 years of age All Phase 3
Y Yuan-Hao Chen

The VALVE-AI Trial

The goal of this clinical trial is to learn if an artificial intelligence-powered electrocardiogram (AI-ECG) can help detect moderate or severe valvular heart diseases (VHD) in adults. The main question it aims to answer is: .Can AI-ECG screening identify patients with significant heart valve diseases who may benefit from early …

60 - 85 years of age All Phase N/A

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

This study evaluates the efficacy and safety of benralizumab as an add-on therapy in uncontrolled eosinophilic asthma participants treated with medium-dose ICS-LABA compared to the conventional treatment step of escalation of inhaled therapy to high-dose ICS-LABA.

12 - 75 years of age All Phase 3

Simplify language using AI